comparemela.com

Latest Breaking News On - Anexus pharmaceuticals - Page 6 : comparemela.com

Lilly hikes revenue forecast by $2B as GLP-1 drug sales climb

BioPharma

United statesNorth carolinaEli lillyAkash tewariDrug administrationAnexus pharmaceuticalsNovo nordiskDive brief

Eli Lilly lifts guidance after sales of Mounjaro and Zepbound drugs soar

Shares of world’s most valuable pharmaceuticals group reapproach record highs

United statesDavid ricksNovo nordiskEli lillyEvan seigermanFinancial timesAnexus pharmaceuticalsDrug administrationWall street

Eli Lilly (LLY) says it can overcome high-quality problem of too much demand

The world's most valuable drugmaker hiked its full-year sales and profit guidance, despite missing lighter-than-expected first-quarter revenue.

United statesDave ricksJim cramerEli lillyJim cramer charitableDrug administrationAnexus pharmaceuticalsNovo nordiskLilly whyPfizer weightWall streetGuidance eli lillyCharitable trustHealth care industryClub earningsInvestment strategy

Eli Lilly rises 6%; company raises 2024 sales forecast by $2 billion

Explosive demand and increased manufacturing capacity for Eli Lilly s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 6%.

North carolinaUnited statesLilly zepboundEli lillyDavid ricksAnexus pharmaceuticalsNovo nordiskDrug administrationWall street

Eli Lilly (LLY) Q1 2024 Earnings Call Transcript

LLY earnings call for the period ending March 31, 2024.

United statesUnited kingdomNorth carolinaPleasant prairieDave ricksKripa devarakondaChris schott jpmorganKerry holford berenbergDan skovronskyLouise chenJames shinLauren zierkiAmerica merrill lynchTerence flynnSeamus fernandezCarter gould

vimarsana © 2020. All Rights Reserved.